Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 8/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7261636 | 0.90 | MAPT (0.52) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL5101120 | 0.89 | PPARG (0.53) | MAPTLMNATP53PPARGPPARA | |
| SCHEMBL5101155 | 0.88 | MAPT (0.53) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL5100503 | 0.84 | LMNA (0.54) | MAPTLMNATP53POLBPPARG | |
| SCHEMBL5081077 | 0.84 | PPARG (0.63) | MAPTLMNATP53PPARGPPARA | |
| SCHEMBL7255050 | 0.84 | PPARG (0.63) | MAPTLMNATP53PPARGPPARA | |
| SCHEMBL14265747 | 0.84 | PPARG (0.63) | MAPTLMNATP53PPARGPPARA | |
| SCHEMBL14265749 | 0.83 | MAPT (0.51) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL14265750 | 0.83 | MAPT (0.51) | MAPTLMNATP53POLBTHRB | |
| SCHEMBL5108315 | 0.83 | LMNA (0.53) | MAPTLMNATP53PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6809095-B2 | NOVEL ANTITOBESITY AND HYPOCHOLESTEROLEMIC COMPOUNDS LOWER TOTAL CHOLESTEROL; INCREASE HIGH DENSITY LIPOPROTEIN (HDL) AND DECREASE LOW DENSTIY LIPOPROTEIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-26 | — | — | US | claimed |
| JP-2002543194-A | — | — | 2002-12-17 | — | — | JP | claimed |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2002-06-27 | — | — | US | claimed |
| EP-1175412-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | Dr. Reddy's Research Foundation (IN) | 2002-01-30 | — | — | EP | claimed |
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY-CHEMINOR, INC. | 2001-12-13 | — | — | US | claimed |
| US-6265401-B1 | ANTIDIABETIC AGENTS | REDDY-CHEMINOR, INC. | 2001-07-24 | — | — | US | claimed |
| EP-1082313-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-03-14 | — | — | EP | claimed |
| WO-2000066572-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-09 | — | — | WO | claimed |
| WO-1999020614-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-29 | — | — | WO | claimed |
| US-7348426-B1 | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents | DR. REDDY'S LABORATIES LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-7348426-B1 | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents | DR. REDDY'S LABORATIES LIMITED (IN) | 2008-03-25 | — | — | US | disclosed |
| US-6846824-B2 | Bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-01-25 | — | — | US | disclosed |
| US-6809095-B2 | NOVEL ANTITOBESITY AND HYPOCHOLESTEROLEMIC COMPOUNDS LOWER TOTAL CHOLESTEROL; INCREASE HIGH DENSITY LIPOPROTEIN (HDL) AND DECREASE LOW DENSTIY LIPOPROTEIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-26 | — | — | US | disclosed |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2002-06-27 | — | — | US | disclosed |
| EP-1175412-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | Dr. Reddy's Research Foundation (IN) | 2002-01-30 | — | — | EP | disclosed |
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY-CHEMINOR, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6265401-B1 | ANTIDIABETIC AGENTS | REDDY-CHEMINOR, INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1082313-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000066572-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTIOBESITY AND HYPOCHOLESTEROLEMIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-09 | — | — | WO | disclosed |
| WO-1999020614-A1 | BICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051619-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CPT1A, GPR119, SLC5A1 | MAPT 209/4885LMNA 664/4885TP53 3892/4885 |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | SLC5A1, CYP11B1, CYP4A11 | MAPT 124/4885LMNA 513/4885TP53 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.